Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) fell $-4.9 during today’s regular trading session, a -6.54% decrease from the previous closing price of $74.87. The company’s shares traded on stronger-than-usual volume today: $4.76M shares changed hands while the stock’s average volume is 1.03M shares per day. Alnylam Pharmaceuticals, Inc. (ALNY) has gained $19.67, or +39.11%, in the last 30 days. This year-to-date, the company’s shares have increased $32.53, or +86.89%. Over the last 12 months, ALNY’s stock price has risen $12.16, or +21.03%. The company’s 52-week range is $31.38 to $80.11.

Alnylam Pharmaceuticals, Inc. (ALNY) Earnings Surprises

Alnylam Pharmaceuticals, Inc. announced its recent quarter financial results after the market close on 05/05/2017, crushing consensus estimates with both its revenue and earnings. Alnylam Pharmaceuticals, Inc. posted net revenue of 18.96M, beating Wall Street analysts who had forecast $23.64M. The company reported EPS of $-1.25, above the consensus estimate calling for EPS of $-1.26 – a negative surprise of -0.73%.

Before that, quarter ending December 2016, Alnylam Pharmaceuticals, Inc. also surprised analysts by beating the consensus estimate. The Wall Street forecast had projected $-1.34 per share, and the company reported EPS of $-1.32 – also a -1.73% negative surprise. Revenue during the period amounted to $17.45M, while analysts were anticipating $10.95M.

In the quarter ending September 2016, Alnylam Pharmaceuticals, Inc. delivered smaller earnings beat. Analysts, on average, were expecting $-1.14 per share, and the company reported EPS of $-1.21 – amounting to a negative surprise of -6.35%. Revenue during that quarter was posted at $13.65M, whereas the consensus estimate was predicting $9.14M.

The company is scheduled to announce its next quarterly financial results on 03/08/2017 after the market close. The average EPS estimate of 6 Wall Street analysts is $-1.23 per share, compared to the company’s reported EPS of $-1.05 per share in the year-ago quarter. Analysts are forecasting Alnylam Pharmaceuticals, Inc. to report revenue of about $22.76M, versus the $8.71M posted last year.

Alnylam Pharmaceuticals, Inc. (ALNY) Consensus Estimates and Price Target

The company’s consensus rating is currently Strong Buy, with 6 analysts rating it a Strong Buy, and 5 analysts rating it with a Hold. The average 12-month price target, as forecast by analysts, is $71.13, 1.66% higher than the company’s closing price today.